NCT02861417View on ClinicalTrials.gov

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

August 5, 2016

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Hematopoietic and Lymphoid Cell NeoplasmHigh Risk Acute Myeloid LeukemiaHigh Risk Myelodysplastic SyndromeLymphoproliferative DisorderMyelodysplastic SyndromeMyelodysplastic/Myeloproliferative NeoplasmRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent High Risk Myelodysplastic SyndromeRecurrent Hodgkin LymphomaRecurrent Myelodysplastic SyndromeRecurrent Non-Hodgkin LymphomaRecurrent Plasma Cell Myeloma
Interventions
PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo stem cell transplantation

DRUG

Busulfan

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Mycophenolate Mofetil

Given PO

OTHER

Pharmacological Study

Correlative studies

DRUG

Tacrolimus

Given IV or PO

DRUG

Thiotepa

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER